Drug Profile
Research programme: cardiovascular disease therapies - Amarin
Alternative Names: EPA derivatives - Amarin; Ethyl eicosapentaenoic acid derivatives - Amarin; Unsaturated fatty acid derivatives - AmarinLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Amarin Corporation; Scarista
- Developer Amarin Corporation
- Class
- Mechanism of Action Phospholipase A2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hyperlipidaemia; Metabolic syndrome
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hyperlipidaemia in United Kingdom (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Metabolic-syndrome in United Kingdom (PO)
- 16 Mar 2015 Pharmacodynamics data from a preclinical trial in Atherosclerosis presented at the 64th Annual Scientific Session of the American College of Cardiology (ACC-2015)